Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jin Medical InternationalZJYL -0.48%64 Debt-to-Equity is 0.69 as of Mar. 2026, which is 77% above its 10-year median of 0.39. GuruFocus rates ZJYL with a GF Score™ of 64/100 and a GF Value™ of $12.85 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 697 Medical Devices & Instruments companies, Jin Medical International ranks worse than 77.62% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Jin Medical International's Debt-to-Equity or its related term are showing as below:
ZJYL'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.39 Max: 0.69
Current: 0.69
During the past 6 years, the highest Debt-to-Equity Ratio of Jin Medical International was 0.69. The lowest was 0.06. And the median was 0.39.
ZJYL's Debt-to-Equity is ranked worse than 77.62% of 697
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs ZJYL: 0.69
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Jin Medical International Debt-to-Equity Related Terms
Jin Medical International Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZJYL vs PDEX, KRMD, STXS: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Jin Medical International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jin Medical International Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Jin Medical International's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Jin Medical International's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jin Medical International (ZJYL) has a Debt-to-Equity of 0.69 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Jin Medical International and its competitors. This is 77% above median its historical median of 0.39. Over the past decade, Jin Medical International's Debt-to-Equity has ranged from 0.06 to 0.69. According to the industry distribution chart, Jin Medical International ranks #541 out of 697 companies in the Medical Devices & Instruments industry, placing it in the top 77.6%.
Is Jin Medical International's Debt-to-Equity too high?
Jin Medical International's current Debt-to-Equity of 0.69 is 77% above median its 10-year median of 0.39. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.69. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. Jin Medical International's value of 0.69 is 187.5% above this industry median. Based on the distribution chart, Jin Medical International ranks #541 out of 697 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Jin Medical International has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jin Medical International's Debt-to-Equity compare to PDEX and KRMD?
According to the Medical Devices & Instruments industry distribution chart, Jin Medical International ranks #541 out of 697 companies for Debt-to-Equity. This places Jin Medical International in the lower half of its industry. The industry median Debt-to-Equity is 0.24. Jin Medical International's value of 0.69 is 187.5% above this benchmark. Historically, Jin Medical International's own Debt-to-Equity has ranged from 0.06 to 0.69 over the past decade. While the company's 10-year median is 0.39 vs. the industry median of 0.24, Jin Medical International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jin Medical International's current Debt-to-Equity of 0.69 is 187.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Jin Medical International and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jin Medical International's current Debt-to-Equity is 0.69, which is 77% above median its own 10-year median of 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jin Medical International stock overvalued right now?
Based on GuruFocus' analysis, Jin Medical International (ZJYL) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.85, compared to a current price of $2.07 — trading 83.9% below its estimated fair value. The current Debt-to-Equity is 0.69, which is 77% above median its 10-year median of 0.39 and 187.5% above the Medical Devices & Instruments industry median of 0.24. Jin Medical International's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Jin Medical International (ZJYL), the current Debt-to-Equity is 0.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jin Medical International (ZJYL) Overvalued in 2026?
Based on GuruFocus' analysis, Jin Medical International stock appears to be undervalued.
The current stock price of $2.07 is trading 83.9% below its estimated GF Value™ of $12.85.
GuruFocus considers Jin Medical International to be Significantly Undervalued.
Key valuation signals for ZJYL:
Debt-to-Equity: 0.69 (77% above median its 10-year median of 0.39)
GF Value™: $12.85 vs. price of $2.07 (83.9% below fair value)
Industry Position: 187.5% above the Medical Devices & Instruments median (#541 of 697)
No single metric tells the full story. See the ZJYL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
64GF Score
Get the complete analysis for ZJYL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZJYL has been successfully added to your 
